Article Text

PDF
Establishing a biologics service for patients with inflammatory bowel disease
  1. P J Hamlin,
  2. L Warren,
  3. S M Everett
  1. Department of Gastroenterology, Leeds Gastroenterology Institute, Leeds General Infirmary, Leeds, UK
  1. Correspondence to Dr P J Hamlin, Department of Gastroenterology, Leeds Gastroenterology Institute, D Floor, Clarendon wing, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK; medjph{at}leeds.ac.uk

Abstract

The use of anti-TNF therapy in the management of Crohn's disease and, to a lesser extent ulcerative colitis, is increasing. This article aims to discuss the practicalities of establishing a biologics service for patients with inflammatory bowel disease. Current guidelines on the use of these drugs are reviewed followed by a discussion on the choice of which anti-TNF agent to use based on costs and patient choice. A model for the initiation, administration, monitoring and assessment of patients receiving anti-TNF therapy is proposed. The need for a national biologics registry is highlighted in the summary.

Statistics from Altmetric.com

Footnotes

  • See linked paper on p144

  • Competing interests PJH and SME were both advisory board members for Schering Plough/MSD and Abbott pharmaceuticals. PJH advised on the draft NICE benchmarking guide for commissioning of anti-TNF therapies. Schering Plough/MSD provided the salary for an IBD clinical nurse specialist in Leeds.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.